What Wall Street Analysts Recommend for Dentsply Sirona

Sarah Collins - Author

Nov. 20 2020, Updated 5:27 p.m. ET

Analyst recommendations for XRAY

Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years. This weak performance was due to the lower-than-expected synergies delivered after the merger of Dentsply International and Sirona Dental Systems in February 2016, which led to the formation of Dentsply Sirona. For more detail, read Inside Dentsply Sirona’s New Turnaround Plan.

In this article, we’ll look at the recent recommendations, ratings, and target prices Wall Street analysts have recommended for Dentsply Sirona.

As of April 9, 2018, 16 analysts were covering XRAY stock. Nearly 62.5% of the analysts have a “buy” or “strong buy” rating on XRAY, and ~31.3% of these analysts gave the stock a “hold” rating. The remaining one analyst gave it a “sell” recommendation.

According to these analysts’ recommendations, the consensus 12-month target price for XRAY is $68.36. This target reflects a potential investment return of ~39.5% from XRAY stock over the next 12 months. XRAY stock closed at $49.02 on April 6, 2018.

Article continues below advertisement

By comparison, Dentsply Sirona’s peers Zimmer Biomet Holdings (ZBH), Danaher (DHR), and Align Technology (ALGN) have average analyst target prices of ~$137.96, $109, and $292.1, respectively. These target prices represent potential returns of 31.2%, 12.8%, and 19.1%, respectively, over the next 12 months.

Recent recommendation revisions and updates

On March 28, 2018, Barclays cut its price target on XRAY stock from $62 to $60. The company initiated coverage of the stock on March 8 with an “equal weight” rating. On March 27, 2018, Barrington Research also cut its target price on XRAY stock from $70 to $69. The research firm cut its target price on XRAY stock on March 5, 2018, as well, from $73 to $70. We’ll discuss the recent decrease in the Dentsply Sirona’s target price by Barrington Research in the next article in this series.

A large number of investment banking firms cut their target prices on Dentsply Sirona’s stock following the company’s 4Q17 earnings results on March 2, 2018. For more detail, read Inside Dentsply Sirona’s 4Q17 Results: Key Highlights.


Latest Align Technology Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.